初治成人急性髓系白血病接受去甲氧柔红霉素联合阿糖胞苷方案诱导化疗的结局
该回顾性研究纳入2008年1月至2016年2月接受IA10方案诱导且获得MLFS后未行allo-HSCT的198例初治成人AML患者,中位随访15个月,2年CIR、DFS、OS分别为45.2%、46.9%、62.9%;初诊不良遗传学特征和CRi独立预测不良结局。
要点
- 198例接受IA10诱导的成人AML患者中,CR率84.8%,CRp率8.1%,CRi率7.1%。
- 2年CIR、DFS、OS率分别为45.2%、46.9%、62.9%,中位复发、DFS、OS时间分别为34、20、37个月。
- FLT3-ITD突变阳性和CRi是影响CIR、DFS、OS的共同不利因素。
核心结论
- 对于接受IA10作为诱导方案且获得MLFS后未接受allo-HSCT的初治成人AML患者,初诊时不良的遗传学特征和CRi是影响总体预后的不利因素。
- 外周血原始细胞比例高、单体核型和巩固治疗1个疗程后MRD阳性也与预后不良相关。
研究设计与样本
- 回顾性分析2008年1月至2016年2月收治的接受IA10方案诱导化疗、获得MLFS后未接受allo-HSCT的198例初治成人AML(非M3)连续病例。
- IA10方案为去甲氧柔红霉素10 mg/m² d1-3联合阿糖胞苷100 mg/m² d1-7。
主要发现
- 198例患者中男96例(48.5%),中位年龄42岁(范围18-62岁)。
- SWOG细胞遗传学分组:低危45例(22.7%)、中危104例(52.5%)、高危24例(12.1%)、未知25例(12.6%);6例(3.0%)有单体核型,28例(14.1%)FLT3-ITD突变阳性。
- CR 168例(84.8%),CRp 16例(8.1%),CRi 14例(7.1%)。
- 131例(66.2%)存活患者中位随访15个月(范围1-70个月),2年CIR、DFS、OS率分别为45.2%、46.9%、62.9%,中位复发、DFS、OS时间分别为34、20、37个月。
- 首次MLFS时多因素分析:FLT3-ITD突变阳性和CRi是影响CIR、DFS、OS的共同不利因素;SWOG高危是影响CIR和DFS的不利因素;单体核型与较短OS相关。
关键数值与推荐
- CR定义为MLFS伴ANC≥1×10⁹/L和PLT≥100×10⁹/L。
- CRp定义为MLFS伴PLT未恢复;CRi定义为MLFS伴ANC和PLT均未恢复。
- MRD阳性定义为RQ-PCR WT1 mRNA≥0.6%或流式细胞术检测到任何水平的异常原始细胞群。
临床怎么用
- 对于接受IA10诱导且未行allo-HSCT的初治成人AML患者,初诊时不良遗传学特征和CRi提示预后不良。
- 巩固治疗1个疗程后外周血原始细胞≥0.50和MRD阳性与预后不良相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To explore outcomes in adult with de novo acute myeloid leukemia (AML) received IA10 (10 mg/m(2) d1-3 idarubicin plus cytarabine 100 mg/m(2) d1-7) regimen as induction chemotherapy. Methods: From January 2008 to February 2016, data of consecutive newly-diagnosed AML (non-M(3)) adults treated with IA10 who achieved morphologic leukemia-free state (MLFS) but not accepted allogeneic hematopoietic stem cell transplantation (allo-HSCT) were assessed retrospectively. Results: A total of 198 patients were included in this study with 96 (48.5%) male and a median age of 42 years old (range, 18-62 years old). Using the SWOG cytogenetic classification, 45 (22.7%), 104 (52.5%), 24 (12.1%) and 25 (12.6%) patients belonged to favorable, intermediate, unfavorable and unknown categories, respectively. 6 (3.0%) patients had monosomal karyotype, and 28 (14.1%) positive FLT3-ITD mutation. A complete remission (CR, defined as MLFS with ANC ≥ 1×10(9)/L and PLT ≥ 100×10(9)/L) achieved in 168 (84.8%) patients, a CRp (defined as MLFS with incomplete PLT recovery) in 16 (8.1%) and a CRi (defined as MLFS with incomplete ANC and PLT recovery) in 14 (7.1%). With a median follow-up period of 15 months (range, 1 to 70 months) in survivors, the probabilities of cumulative incident of relapse (CIR), disease free survival (DFS) and overall survival (OS) rates at 2-year were 45.2%, 46.9% and 62.9%, respectively; the median durations of relapse, DFS and OS were 34, 20 and 37 months respectively. At the time of achieving first MLFS, multivariate analyses showed that positive FLT3-ITD mutation and CRi were common adverse factors affecting CIR, DFS and OS; unfavorable-risk of SWOG criteria was an adverse factor affecting CIR and DFS; monosomal karyotype was associated with shorter OS. After first consolidation therapy, FLT3-ITD mutation positive and unfavorable-risk of SWOG criteria had negatively impact on CIR, DFS and OS; peripheral blasts ≥ 0.50 and positive MRD (defined as RQ-PCR WT1 mRNA ≥ 0.6% or any level of abnormal blast population detected by flow cytometry) after first consolidation therapy were common adverse factors affecting CIR and DFS; CRi was an adverse factor affecting DFS and OS. Conclusions: In adult with de novo AML received IA10 regimen as induction regimen, unfavorable molecular markers or cytogenetics at diagnosis and CRi independently predicted poor outcome. In addition, a higher percentage of peripheral blasts, monosomal karyotype and positive MRD after first consolidation therapy had negatively impact on outcomes. 目的: 探讨接受IA10[去甲氧柔红霉素(IDA)10 mg·m(-2)·d(-1)×3 d联合阿糖胞苷(Ara-C)100 mg·m(-2)·d(-1)×7 d]作为诱导方案且未接受异基因造血干细胞移植(allo-HSCT)的成人急性髓系白血病(AML)患者的预后影响因素。 方法: 回顾2008年1月至2016年2月收治的接受IA10作为诱导化疗方案、获得形态学无白血病状态(MLFS)后未接受allo-HSCT的198例AML(不包括急性早幼粒细胞白血病)连续病例,分析诊断时特征、首次获得MLFS时血细胞恢复程度、首次获得MLFS时和巩固1个疗程后微小残留病(MRD)水平对预后的影响。 结果: 198例患者中,男96例(48.5%),中位年龄42(18~62)岁。SWOG分组:低危45例(22.7%),中危104例(52.5%),高危24例(12.1%),危险度未知25例(12.6%)。FLT3-ITD突变阳性28例(14.1%)。完全缓解(CR,MLFS伴ANC≥1×10(9)/L和PLT≥100×10(9)/L)168例(84.8%),CRp(MLFS伴PLT未恢复)16例(8.1%),CRi(MLFS伴ANC和PLT均未恢复)14例(7.1%)。131例(66.2%)存活患者中位随访时间15(1~70)个月,2年累积复发率(CIR)、无病生存(DFS)、总生存(OS)率分别为45.2%、46.9%、62.9%,中位复发、DFS、OS时间分别为34、20、37个月。在所有获得MLFS的患者中进行多因素分析,FLT3-ITD突变阳性和CRi是影响患者CIR、DFS、OS的共同不利因素;SWOG危险度为高危是影响患者CIR和DFS的共同不利因素;单体核型是影响患者OS的独立危险因素。分析接受巩固治疗≥1个疗程的患者,FLT3-ITD突变阳性和SWOG危险度为高危是影响患者CIR、DFS、OS的共同不利因素;外周血原始细胞≥0.50和巩固治疗1个疗程后MRD阳性[FCM和(或)WT1 mRNA阳性]是影响患者CIR和DFS的共同不利因素;CRi是影响患者DFS和OS的共同不利因素。 结论: 对于接受IA10作为诱导方案且获得MLFS后未接受allo-HSCT的初治成人AML患者,初诊时不良的遗传学特征和CRi是影响患者总体预后的不利因素。此外,外周血原始细胞比例高、单体核型和巩固治疗1个疗程后MRD阳性也与预后不良相关。.
引用
- Ren X, Zhao T, Wang J, et al. [Outcomes of adult patients with de novo acute myeloid leukemia received idarubicin plus cytarabine regimen as induction chemotherapy]. Zhonghua Xue Ye Xue Za Zhi. 2018. PMID: 29551027. doi:10.3760/cma.j.issn.0253-2727.2018.01.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。